Who are Anti-PD-L1 Monoclonal Antibody's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DURVALUMAB, AVELUMAB, Adebrelimab combined with SOX regimen, Cisplatin / Carboplatin，Gemcitabine，Cindilimab, Pf-06835375, Atezolizumab Injection [Tecentriq].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-pd-l1-monoclonal-antibody.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Anti-PD-L1 Monoclonal Antibody — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-PD-L1 Monoclonal Antibody (Anti-PD-L1 Monoclonal Antibody) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor. Area: Oncology.

phase 2 PD-1 inhibitor PD-L1 Oncology Biologic Live · refreshed every 30 min

Target snapshot

Anti-PD-L1 Monoclonal Antibody (Anti-PD-L1 Monoclonal Antibody) — City of Hope Medical Center. Anti-PD-L1 Monoclonal Antibody works by blocking the PD-L1 protein, allowing the immune system to attack cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-PD-L1 Monoclonal Antibody TARGET	Anti-PD-L1 Monoclonal Antibody	City of Hope Medical Center	phase 2	PD-1 inhibitor	PD-L1
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
AVELUMAB	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
Adebrelimab combined with SOX regimen	Adebrelimab combined with SOX regimen	Yang Jianjun, PhD	marketed	PD-L1 inhibitor	PD-L1
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
Pf-06835375	pf-06835375	Pfizer	marketed	Immunotherapy	PD-L1
Atezolizumab Injection [Tecentriq]	Atezolizumab Injection [Tecentriq]	Nykode Therapeutics ASA	marketed	PD-L1 inhibitor	PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor class)

Sun Yat-sen University · 11 drugs in this class
Bristol-Myers Squibb · 9 drugs in this class
Addpharma Inc. · 7 drugs in this class
Merck Sharp & Dohme LLC · 5 drugs in this class
Shanghai Henlius Biotech · 5 drugs in this class
Innovent Biologics (Suzhou) Co. Ltd. · 5 drugs in this class
Pfizer · 4 drugs in this class
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 4 drugs in this class
Amgen · 3 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-PD-L1 Monoclonal Antibody — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-pd-l1-monoclonal-antibody. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab